



23 April 2009

Norgine Partners with PharmaSwiss for MOVIPREP® in Eastern Europe

Norgine, the leading European specialty pharmaceutical company is delighted to announce that it has appointed PharmaSwiss as its marketing partner in a number of markets in Eastern Europe. The precise details of the deal have not been announced.

MOVIPREP is a novel patent protected product developed by Norgine for bowel cleansing prior to colonoscopy and other situations where a clean bowel is required. The product is currently marketed by Norgine in Europe and by Salix, Norgine's marketing partner in the USA.

"This agreement further strengthens Norgine's commitment to bring innovative products to the market for the benefit of patients worldwide" commented Norgine's CEO Peter Stein.

ENDS

Notes to editor

Norgine is an independent, successful European specialty pharmaceutical company that has been established for over 100 years and has a presence in all the major European markets. In 2007 Norgine's sales were €220 million, the 21st consecutive year of double-digit growth. The company employs over 1,000 people many of whom work in the sales, marketing and manufacturing functions.

Norgine's current focus is pharmaceutical products that address significant unmet clinical needs in areas such as gastroenterology, hepatology and pain management. The company currently markets a range of products in its key therapeutic areas e.g., MOVICOL® for the treatment of constipation and faecal impaction, MOVIPREP a new generation of bowel cleansing preparation, KLEAN-PREP® for bowel preparation prior to colonoscopy, XIFAXAN® for the treatment of travellers diarrhoea and ORAMORPH® for the treatment of moderate to severe pain associated with cancer.

Norgine is active in research and development and currently has products in various stages of clinical development. Norgine manufactures most of its own products in Hengoed, Wales and Dreux in France.

Norgine's web site www.norgine.com

For further information, please contact:
Julie Hornby Winfield. Global Corporate Communications Manager
T: +44 (0)1895 826642
E: jhornbywinfield@norgine.com

About PharmaSwiss SA

Established in 2000 and based in Zug, Switzerland, PharmaSwiss offers full third-party representation of specified drugs or portfolios from research-based pharmaceutical and biotech companies, including drug registration, promotion, sales, compliance and pharmacovigilance. It represents several blue chip clients such as Amgen, Bristol-Myers Squibb, Wyeth Pharmaceuticals, Ipsen, Astellas Pharma, Eli Lilly and Ferring. PharmaSwiss currently operates in Serbia, Croatia, Slovenia, Poland, Baltic countries, Czech Republic, Hungary, Romania, Bulgaria, Slovakia, Albania, Greece, Turkey and Israel. During the course of 2008, PharmaSwiss has launched operations in Hungary, Romania and Turkey and during 2009 in Poland. Development plans for the following years include also entering Russia and CIS. The company has nearly 600 employees and achieved turnover of €132 million in 2008. Total 2008 sales, including managed sales (Greece & Turkey), were EUR180+MM; 2009 will be over 225MM (Greece and Turkey inclusive).

For more information, please visit: www.pharmaswiss.com